CareDx, Inc.

Today, we reported our second quarter 2026 results, closing out a quarter of strong growth and transformation. Read more in our press release: https://lnkd.in/gHfQtMhC

Featured in a Medtech Insight article from Citeline, CareDx CEO John Hanna discusses how we're extending our precision diagnostics expertise beyond transplant into specialty oncology and cell therapy. Read the full interview (registration may be required): https://lnkd.in/eswN7Vmv #PrecisionMedicine #Oncology #Transplant #CellTherapy #MolecularDiagnostics #HealthcareInnovation #Biotech

Featured today in the San Francisco Business Times: a look at where CareDx is headed next. CEO John Hanna discusses our expansion into specialty oncology and how we're building on nearly three decades of expertise in precision medicine diagnostics. Following the acquisition of NavDx, we're combining a proven commercial and operational foundation with innovative HPV-driven cancer detection technology to broaden our impact in patient care. As Hanna shared: "We've built a platform to rapidly launch new products and integrate acquisitions with the same level of service." Read the full story: https://bizj.us/1qqdyg  #HealthcareInnovation #CancerDiagnostics #PrecisionMedicine #Biotech

Today, we announced the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. Dr. Jeff Teuteberg, Chief Medical Officer of CareDx, shared: “The final policy reinforces the role of molecular surveillance in transplant patient management, providing important clarity for patients and clinicians." Read more about the coverage in our press release: https://lnkd.in/gd6G_kPh

Big news! CareDx has been named a 2026 Axios Greater Bay Area Top Workplace. This recognition reflects feedback from our employees and highlights the collaboration, care, and commitment our team brings every day. We're grateful for the incredible people who make CareDx such a great place to work, and who make awards like this possible. #TopWorkplace #CareDx #SFBayArea

The Transplant Games of America this year in Denver brought together transplant recipients, donors, and donor families in an incredible way. The stories, competition, and sense of community were a powerful reminder of the impact of transplantation and the many ways people go on to live full, vibrant lives beyond it. CareDx served as the presenting sponsor of the 2026 Games and had the opportunity to experience these moments firsthand. Thank you to everyone who participated, spent time with us, and made this year’s Games truly unforgettable. #TransplantGames2026 #TGA26Denver #Transplant

It's official! We're thrilled to welcome Naveris, Inc. to CareDx, extending our leadership into high-growth specialty oncology. Naveris's lead product, NavDx®, is a blood-based test that detects and monitors viral-mediated cancers — including HPV-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD. With this acquisition, we now offer a portfolio of precision diagnostic testing services across solid organ transplant, cell therapy-based hematologic malignancies, and viral-mediated cancers. Read more in our press release: https://lnkd.in/gW4955dJ #PrecisionMedicine #Oncology #MRD

The latest ISHLT Journal Watch highlights the second SHORE manuscript, reinforcing the role of noninvasive molecular biomarker testing in heart transplant surveillance and the broader shift toward approaches like HeartCare.

Today, we announced the closing of the previously announced sale of our Lab Products business to Eurobio Scientific. John Hanna, President and CEO of CareDx, shared: "This transaction sharpens CareDx's focus on our core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, where our integrated model continues to deliver strong growth." Read the full announcement: https://lnkd.in/gNEnJZTT

We're heading to #ATC2026Boston, where our precision medicine diagnostics will be featured in over 30 abstracts and 9 oral presentations, with data generated from studies at more than 110 U.S. transplant centers. The data span kidney, heart, lung, and multi-organ transplantation and reflect the continued evolution of AlloSure® dd-cfDNA from an emerging biomarker to a potential clinical endpoint, with studies now utilizing AlloSure to assess allograft injury, monitor treatment response, and evaluate long-term graft health in kidney transplantation. Swipe to see key highlights → https://lnkd.in/gyq-tT-w #Transplant #PrecisionMedicine #Diagnostics #KidneyTransplant #HeartTransplant #LungTransplant Jeff Teuteberg